The US Center for Breakthrough Medicines (CBM), a Cell and Gene Therapy Contract Organization for Development, Manufacturing, and Testing, has entered into a licencing agreement with Autolomous LTD, the market-leading developer of critical manufacturing management systems for cell and gene therapies (CGT) (CDMO).
With the help of the agreement, Autolomous will be able to design, set up, and integrate solutions for CBM using the AutoMATE® platform, a robust, mission-critical digital platform that gives CBM seamless digital connectivity in production operations across all key components (like investment systems and technologies) of the full cell and gene therapy (CGT) value chain.
“As manufacturing demand for cell and gene therapies accelerates, leveraging manufacturing insights will become increasingly important”, “Autolomous will support CBM, the world’s largest custom CGT manufacturing site, to deliver an in primarily enabling digital manufacturing platform. Autolomous will continue to deliver significant innovations that maximize manufacturing productivity and eliminate bottlenecks through automation and digitalization, while lowering the cost of products to improve patient access to these life-saving therapies.”
Alexander Seyf, CEO, Autolomous
In order to improve operational learning, reduce response times for compliance, and promote shorter investigation deadlines, Autolomous will help CBM convert all batch record reviews (batch documentation at the end of the production process) to electronic. This will result in centralised data visibility, which will lower product costs, increase productivity, and increase manufacturing scalability for CBM.
“Working with Autolomous enables CBM to digitize our entire supply chain ecosystem and ensure transparency throughout the process, while maintaining full data integrity, full quality assurance and control, and automating key parts of the manufacturing process, such as performing calculations and the transcription of data from Batch Manufacturing Records (BMRs)”, “While we strive to make advanced therapies available and affordable for every patient, the AutoloMATE® platform positions CBM to offer our customers the most advanced technology to advance their CGT manufacturing and save more lives.”
Jeet Sarkar, VP, Head of IT, CBM
